March 07, 2023
Biotechnology giant Amgen has urged the U.S. Supreme Court not to "distort enablement law" as justices review a Federal Circuit decision axing patents on its cholesterol drug Repatha, arguing that Sanofi is a walking contradiction when it comes to the patent challenger's stance on enablement requirements.
February 21, 2023
The U.S. Supreme Court on Tuesday cleared the government to participate alongside Sanofi and Regeneron in upcoming oral arguments over patent enablement, but refused an arm of the American Chemical Society's uninvited attempt to join Amgen.
February 13, 2023
The federal government, various drug companies and a molecular biologist who won the Nobel Prize for his work with monoclonal antibodies urged the U.S. Supreme Court to keep the standard of patent enablement as is, backing Sanofi and Regeneron in their fight against Amgen.
February 03, 2023
Sanofi and Regeneron on Friday urged the U.S. Supreme Court to reject Amgen's arguments that it deserves broad patent coverage on cholesterol drugs the rivals both sell, in the one patent case the justices have agreed to hear this term.
January 05, 2023
Amgen Inc. on Thursday urged the U.S. Supreme Court to deny a chemistry organization's request to speak at oral arguments in a high-profile fight over the standard for a patent to meet enablement requirements.
January 03, 2023
Massive drug companies, early-stage startups and a wide range of intellectual property groups were among many parties Tuesday urging the U.S. Supreme Court to hold that the Federal Circuit erred when invalidating Amgen patents in a fight over how to interpret when a patent meets enablement requirements.
January 02, 2023
The Supreme Court's foray into what it takes to enable someone to make a patented invention, the patent infringement implications of labels on generic drugs and a dispute over which arguments can be in court following an inter partes review are among the patent cases attorneys will be tracking this year.
November 10, 2022
The U.S. Supreme Court has decided to review a patent case about enablement that the solicitor general explicitly recommended against, a move attorneys found surprising, especially given the justices' unprecedented decision to deny a patent eligibility case the government backed just months before.
November 04, 2022
The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.
October 05, 2022
In urging the U.S. Supreme Court to reject an appeal by Amgen involving the patent enablement requirement, the U.S. solicitor general has stated an expansive view of the provision that may be impossible for some inventions to meet, experts say.